Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Ebola Antiviral Assay (EBOV) from US Patent US11149049: "Substituted nucleosides, nucleotides and analogs thereof"
Assay data:5 Active, 4 Activity ≤ 1 µM, 5 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Inhibition of HIV/EBOV GP T519V mutant infected in 293T cells assessed as reduction in virus entry
Assay data:2 Active, 1 Activity ≤ 1 µM, 2 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of HIV/EBOV GP Y517S mutant infected in 293T cells assessed as reduction in virus entry
Assay data:2 Active, 1 Activity ≤ 1 µM, 3 Tested
Binding affinity to Ebola virus Zaire Mayinga-76 recombinant GP protein by SYPRO orange dye-based fluorescence assay
Assay data:5 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of Ebola virus Sudan envelope glycoprotein-mediated cell entry in human HuH7 cells treated with 30 mins pre-treated pseudovirus/compopund mixture and measured after 72 hrs by luciferase reporter assay
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Antiviral activity against Ebola virus - Mayinga, Zaire, 1976 infected in human HeLa cells assessed as inhibition of viral infection pretreated for 2 hrs before viral infection and measured after 48 hrs by EboV GP immunostaining based method
Assay data:4 Active, 4 Activity ≤ 1 µM, 4 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed Citation
Binding affinity to EBOV Mayinga, Zaire, 1976 envelope glycoprotein extracellular domain T42A mutant tagged with 6xHis/foldon trimerization sequence from the bacteriophage T4 fibritin at C terminal expressed in HEK293T cells at pH 5.2 by SYPRO orange dye-based fluorescence assay
Assay data:1 Tested
Binding affinity to glycoprotein Y517S mutant in pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells at 0.12 to 250 uM assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay
SummaryPubMed Citation
Binding affinity to glycoprotein L184M mutant in pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells at 0.12 to 250 uM assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay relative to wild type
Assay data:4 Tested
Binding affinity to glycoprotein L515V mutant in pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells at 0.12 to 250 uM assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay relative to wild type
Binding affinity to glycoprotein P187E mutant in pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells at 0.12 to 250 uM assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay relative to wild type
Binding affinity to glycoprotein R64K mutant in pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells at 0.12 to 250 uM assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay relative to wild type
SummaryCompounds, ActivePubMed Citation
Binding affinity to glycoprotein V66M mutant in pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells at 0.12 to 250 uM assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay relative to wild type
Binding affinity to glycoprotein E100D mutant in pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells at 0.12 to 250 uM assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay relative to wild type
Binding affinity to glycoprotein T502S mutant in pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells at 0.12 to 250 uM assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay relative to wild type
Assay data:1 Active, 3 Tested
Inhibition of Vesicular stomatitis virus particle bearing EBOV glycoprotein-mediated viral entry in African green monkey Vero cells at 20 uM incubated for 1 hr prior to viral addition measured after 1 hr by fluorescence microscopy relative to control
Assay data:3 Active, 3 Tested
Inhibition of Vesicular stomatitis virus particle bearing EBOV glycoprotein-mediated viral entry in African green monkey Vero cells incubated for 1 hr prior to viral addition measured after 1 hr by fluorescence microscopy relative to control
Assay data:2 Active, 2 Tested
Binding affinity to Ebola virus Zaire Mayinga-76 recombinant GP protein assessed as change in melting temperature at 500 uM by SYPRO orange dye-based fluorescence assay
Antiviral activity against Ebola virus Mayinga Zaire 1976 infected in IFNAR-/- C57BL/6 mouse at 300 mg/kg, po administered twice daily measured up to 6 days post infection
Antiviral activity against Ebola virus Mayinga Zaire 1976 infected in IFNAR-/- C57BL/6 mouse assessed as biochemical correlates of disease at 300 mg/kg, po administered twice daily
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on